EC Number   |
Recommended Name |
Application  |
|---|
   3.4.14.5 | dipeptidyl-peptidase IV |
veterinary medicine |
inhibition of intragraft DPP IV enzymatic activity significantly reduces ischemia/reperfusion-associated pulmonary injury, allowing for successful transplantation after 18 h of ischemia |
| 3.4.14.5 | dipeptidyl-peptidase IV |
veterinary medicine |
inhibiting intragraft DPP IV enzymatic activity in a rat single-lung transplantation model abolishes ischemia/reperfusion injury after extended ischemia |
| 3.4.15.1 | peptidyl-dipeptidase A |
veterinary medicine |
angiotensin-converting enzyme inhibitors are recommended in dogs and cats with chronic renal failure. They decrease the glomerular capillary pressure, have antiproteinuric effects, tend to delay the progression of chronic renal failure and to limit the extent of renal lesions |
| 3.4.15.1 | peptidyl-dipeptidase A |
veterinary medicine |
candesartan (angiotensin II type 1 receptor blocker) and enalapril (angiotensin-converting-enzyme inhibitor) during healing after reperfused ST-elevation myocardial infarction prevent rather than worsen adverse remodeling of infarct zone collagens and left ventricular diastolic dysfunction, supporting the clinical use of ARBs and ACEIs during subacute reperfused ST-elevation myocardial infarction |
| 3.4.15.1 | peptidyl-dipeptidase A |
veterinary medicine |
the combination of an angiotensin converting enzyme inhibitor and spironolactone is safe in elderly small dogs with mitral valve disease with normal serum urea nitrogen and creatinine concentrations |
